33.87
+0.02(+0.06%)
Currency In USD
| Previous Close | 33.85 |
| Open | 33.54 |
| Day High | 34.22 |
| Day Low | 33.37 |
| 52-Week High | 39.47 |
| 52-Week Low | 21.62 |
| Volume | 1.36M |
| Average Volume | 2.97M |
| Market Cap | 6.44B |
| PE | -11.76 |
| EPS | -2.88 |
| Moving Average 50 Days | 33.7 |
| Moving Average 200 Days | 28.81 |
| Change | 0.02 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $1,229.4 as of April 19, 2025 at a share price of $33.87. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $1,226.29 as of April 19, 2025 at a share price of $33.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
GlobeNewswire Inc.
Mar 31, 2025 2:00 PM GMT
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysisThis profound treatment effect, due to the near-complete
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
GlobeNewswire Inc.
Mar 27, 2025 11:00 AM GMT
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most ra
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
GlobeNewswire Inc.
Mar 24, 2025 11:30 AM GMT
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in pa
Data not available